Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

[1]  L. Tokgözoğlu,et al.  Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach. , 2022, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[2]  M. Sabatine,et al.  Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 , 2022, Circulation.

[3]  R. Rosenson,et al.  New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4. , 2021, Journal of the American College of Cardiology.

[4]  R. Rosenson,et al.  The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis , 2021, Lipids in Health and Disease.

[5]  D. Gaudet,et al.  Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. , 2021, Journal of the American College of Cardiology.

[6]  R. Rosenson,et al.  Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction , 2021, Cardiovascular Drugs and Therapy.

[7]  D. Rader,et al.  ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[8]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[9]  D. Gaudet,et al.  Evinacumab for Homozygous Familial Hypercholesterolemia. , 2020, The New England journal of medicine.

[10]  R. Hegele,et al.  Genetics of Hypertriglyceridemia , 2020, Frontiers in Endocrinology.

[11]  Jonathan C. Cohen,et al.  Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance , 2020, Journal of Lipid Research.

[12]  D. Karalis,et al.  Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association , 2020, Journal of General Internal Medicine.

[13]  R. Hegele,et al.  Clinical review on triglycerides , 2019, European heart journal.

[14]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[15]  W. Sasiela,et al.  Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia , 2019, Circulation.

[16]  J. Borén,et al.  Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD , 2019, Current Atherosclerosis Reports.

[17]  R. Hegele,et al.  Severe hypertriglyceridemia is primarily polygenic. , 2019, Journal of clinical lipidology.

[18]  G. Wang,et al.  Elevated Serum Triglycerides in the Prognostic Assessment of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies , 2017, Journal of clinical gastroenterology.

[19]  D. Gaudet,et al.  ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. , 2017, The New England journal of medicine.

[20]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[21]  J. Danesh,et al.  ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.

[22]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[23]  D. Gaudet,et al.  Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. , 2014, Journal of the American College of Cardiology.

[24]  P. Talmud,et al.  Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets* , 2013, The Journal of Biological Chemistry.

[25]  Colin D Johnson,et al.  Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus , 2012, Gut.

[26]  K. Lowe,et al.  Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. , 2011, The American journal of cardiology.

[27]  Jonathan C. Cohen,et al.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.

[28]  M. Matsuda,et al.  Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  A. Gotto,et al.  Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[30]  R. Ramakrishnan,et al.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. , 1997, The Journal of clinical investigation.